Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects

NCT00414778 | Completed Phase 1

• 1 other identifier: CLHT344A2101
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate safety and pharmacokinetics of a single and multiple dose of LHT344 in 12 Chinese healthy subjects. This study is not recruiting subjects in the United States.

Conditions

Healthy

Keywords

Safety, pharmacokinetics, oral, single dose, multiple dose, LHT344, Chinese, healthy subjects

Outcome Measures

Primary Outcomes (1)

• Pharmacokinetics of single and repeat daily oral dose of LHT344 in Chinese healthy subjects

Secondary Outcomes (1)

• Safety of single and repeat daily oral dose of LHT344 in Chinese healthy subjects

Interventions

LHT344 DRUG

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy, non-smoking, male or female subjects age 18 to 45 years of age
• In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation
• Body mass index within the range of 19 to 24 kg/m2 and weigh at least 50 kg

You may not qualify if:

• Smokers
• Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Paracetamol is acceptable.
• Participation in any clinical investigation within 3 months prior to dosing.
• Donation or loss of 400 mL or more of blood within 12 weeks prior to first dosing required by local regulation.
• Significant illness within 2 weeks prior to dosing.
• A past personal or close family medical history of clinically significant cardiac abnormalities such as a myocardial infarction, angina, arterial fibrillation, arrhythmia or hypertension.
• History of
• fainting, low blood pressure upon standing, irregular heart beats
• acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
• clinically significant drug allergy, history or presence of atopic allergy (asthma, urticaria, eczematous dermatitis)
• known hypersensitivity to the study drug or similar drugs
• surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or may jeopardize the subject participation in the study
• immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
• positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
• drug or alcohol abuse within the 12 months prior to study participation

Sponsors & Collaborators

• Novartis: lead

Study Sites (1)

Novartis Investigative Site

Beijing, China

Location

Study Officials

• Novartis

  Investigator site

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: December 21, 2006
• First Posted: December 22, 2006
• Study Start: October 1, 2006
• Primary Completion: October 1, 2006
• Last Updated: January 13, 2011

Record last verified: 2011-01

Locations

CN (1)